Cloud-Clone expands skin research portfolio with 40+ primary cell types

Wuhan Cloud-Clone Corp. says it now offers more than 40 primary cell types for epidermal, dermal, skin appendage and mucosal models, backed by full-chain quality control and SPF-grade animal facilities. The portfolio is aimed at wound repair, fibrosis, inflammation, oncology and drug-screening research across multiple species.

Why it matters: - Primary cells are the starting point for skin and mucosal research into injury repair, disease mechanisms and drug screening. - Cloud-Clone is positioning a broader, quality-controlled cell portfolio for researchers who need consistent purity, viability and differentiation status. - The company says the expanded offering supports more relevant in-vitro models for studying skin disease and testing compounds.

What happened: - Wuhan Cloud-Clone Corp. said it offers more than 40 skin-system primary cell types for epidermal, dermal, skin appendage and mucosal models. - The company said the portfolio is backed by a full-chain quality-control workflow covering animal breeding, tissue harvesting, cell isolation, characterisation and product delivery. - Cloud-Clone said the offering is available across more than ten species, including human, mouse, rat, rabbit, dog, cat, pig, sheep, guinea pig and chicken. - The company said its broader catalogue includes more than 600 primary cell products.

The details: - Cloud-Clone operates a 1,200 m² SPF-grade laboratory animal centre with standardized IVC housing systems. - The company said every step from animal breeding to tissue collection is managed internally. - Cloud-Clone said its animals are raised from birth in a proprietary SPF breeding system to minimise pathogen contamination and preserve cell purity and viability. - The company offers customised tissue sourcing and disease-model tissue procurement services. - Cloud-Clone said its quality framework includes ISO quality-system certification, accredited SPF-grade animal facilities and regulatory permits for animal epidemic prevention, laboratory animal production and laboratory animal use. - Skin and mucosal products include epidermal keratinocytes, lingual epidermal cells, dermal fibroblasts, dermal microvascular endothelial cells, subcutaneous pre-adipocytes, adipose microvascular endothelial cells and oral keratinocytes. - The company said the cells are used to study physiological mechanisms, injury-repair pathways, pathogenic-gene validation, disease-model establishment and screening of new drugs and functional raw materials. - Representative product examples listed in the release include mouse neonatal epidermal keratinocytes, mouse dermal microvascular endothelial cells, feline adult dermal fibroblasts and rat neonatal dermal fibroblasts.

Between the lines: - Cloud-Clone is using quality-control claims as a differentiator in a research market where contamination, variability and poor reproducibility can undermine experiments. - The emphasis on internal breeding, tissue sourcing and validation suggests the company is trying to control more of the supply chain than many cell suppliers. - The release also ties product credibility to external use, noting that primary mouse dermal fibroblasts from the company were adopted in a diabetes-associated skin wound-healing study published in Nature Communications.

What's next: - Cloud-Clone said it will continue supplying specialised skin- and mucosa-related primary cell lines alongside its larger cell catalogue. - The company said the cells are intended for global research communities studying skin and mucosal physiology, tissue injury repair and associated diseases. - The release points to ongoing use in wound repair, inflammation, barrier dysfunction, fibrosis, oncology, adipose metabolism and in-vitro pharmacological screening.

The bottom line: - Cloud-Clone is betting that breadth plus documented quality control will make its skin and mucosal primary cells more attractive for mechanistic research and drug-testing workflows.